Replies to post #138982 on Biotech Values

[DewDiligence]

Whether or not WPI itself is overvalued, paying ~3x sales to acquire Actavis strikes me as excessive and is symptomatic of empire building. If they can get it for only 2x sales, it’s a different story.

[DewDiligence]

It’s official—WPI acquires Actavis for €4.25B ($5.6B), creating #3 worldwide player in generic drugs (behind TEVA and NVS):

http://finance.yahoo.com/news/watson-acquire-actavis-group-eur4-200000467.html

…Watson will acquire Actavis for an upfront payment of EUR4.25 billion. Actavis stakeholders could also receive additional consideration, contingent upon Actavis achieving negotiated levels of certain 2012 performance targets. The contingent payment, if fully earned, would result in the delivery of up to 5.5 million shares of Watson common stock in 2013. This contingent payment was valued during the negotiations at EUR250 million, based on a per share price of $60, using a Euro to U.S. dollar exchange rate of 1.32.

A CC was held at 4:30pm ET (http://www.videonewswire.com/event.asp?id=85954 ); it should be available for replay by now.